ERBB2 and breast cancer: They observed that IL-17A and MIF are higher in aggressive molecular subtypes TN, Luminal B, and HER2 compared to less aggressive Luminal A. Their results showed that an increase in the expression of both Th17 and MIF enhanced the risk of BC, indicating that simultaneous blockade of these factors could be an effective strategy to inhibit BC progression [100].